Clinical trials: C.Difficile Diarrhea, open to volunteers
Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea
Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.
- Trial name
- NCT06839209
- Testing
- Toxclean 1g
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- ABResearch S.r.l.
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Active C. Difficile Colitis
Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea
The study is on indefinite HOLD due to the loss of funding that occurred during the pandemic emergency. Subsequently, a key collaborator left our institution, and as a near-term result, the protocol awaits reactivation.
- Trial name
- NCT01868373
- Testing
- Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Clostridioides Difficile Infection, Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident…
- Conditions
- Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
- Trial name
- ACT (NCT04305769)
- Testing
- Alanyl-glutamine
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of Virginia